• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization).

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

出版信息

Liver Cancer. 2024 May 13;13(4):335-343. doi: 10.1159/000539301. eCollection 2024 Aug.

DOI:10.1159/000539301
PMID:39114759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11305789/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/c23b7bf458d5/lic-2024-0013-0004-539301_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/cc6c8e081065/lic-2024-0013-0004-539301_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/5920ee933dcd/lic-2024-0013-0004-539301_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/1db655b3f126/lic-2024-0013-0004-539301_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/c23b7bf458d5/lic-2024-0013-0004-539301_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/cc6c8e081065/lic-2024-0013-0004-539301_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/5920ee933dcd/lic-2024-0013-0004-539301_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/1db655b3f126/lic-2024-0013-0004-539301_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4057/11305789/c23b7bf458d5/lic-2024-0013-0004-539301_F03.jpg

相似文献

1
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization).经动脉化疗栓塞术在免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂加经动脉化疗栓塞术时代的角色转变：从完全栓塞到部分栓塞（免疫增强经动脉化疗栓塞术）
Liver Cancer. 2024 May 13;13(4):335-343. doi: 10.1159/000539301. eCollection 2024 Aug.
2
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.经动脉化疗栓塞联合酪氨酸激酶抑制剂加免疫检查点抑制剂与酪氨酸激酶抑制剂加免疫检查点抑制剂治疗不可切除的伴有一级或低级别门静脉癌栓的肝细胞癌。
Cardiovasc Intervent Radiol. 2024 Jun;47(6):751-761. doi: 10.1007/s00270-024-03724-x. Epub 2024 Apr 26.
3
Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.经动脉化疗栓塞在不可切除肝细胞癌的酪氨酸激酶抑制剂和免疫检查点抑制剂联合治疗时代的作用：回顾性倾向评分匹配分析。
Acad Radiol. 2024 Apr;31(4):1304-1311. doi: 10.1016/j.acra.2023.09.001. Epub 2023 Sep 27.
4
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.经动脉化疗栓塞联合 PD-1 抑制剂加仑伐替尼治疗不可切除肝细胞癌的疗效优于 PD-1 抑制剂加仑伐替尼。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231166765. doi: 10.1177/15330338231166765.
5
Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.索拉非尼、仑伐替尼或仑伐替尼联合 PD-1 抑制剂联合 TACE 治疗不可切除肝细胞癌：回顾性分析。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221133640. doi: 10.1177/15330338221133640.
6
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.经动脉化疗栓塞术的加入可改善不可切除肝细胞癌患者酪氨酸激酶和免疫检查点抑制剂治疗方案的疗效。
J Gastrointest Oncol. 2023 Aug 31;14(4):1837-1848. doi: 10.21037/jgo-23-486. Epub 2023 Aug 14.
7
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.免疫检查点抑制剂和抗血管内皮生长因子抗体/酪氨酸激酶抑制剂联合或不联合经动脉化疗栓塞作为晚期肝细胞癌一线治疗方案（CHANCE2201）：一项目标试验模拟研究
EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun.
8
Prevalence and Risk Factors of Post-chemoembolization Syndrome After Chemo-Embolization for Hepatocellular Carcinoma in Thailand.泰国肝细胞癌化疗栓塞术后化疗栓塞综合征的患病率及危险因素。
Dig Dis Sci. 2023 Sep;68(9):3818-3823. doi: 10.1007/s10620-023-08010-3. Epub 2023 Jul 4.
9
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.经动脉化疗栓塞术（TACE）联合酪氨酸激酶抑制剂和免疫检查点抑制剂治疗不可切除肝细胞癌的意义：系统治疗时代的系统评价。
Front Immunol. 2022 May 23;13:913464. doi: 10.3389/fimmu.2022.913464. eCollection 2022.
10
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.经动脉化疗栓塞术联合仑伐替尼对比经动脉化疗栓塞术联合索拉非尼作为伴门静脉癌栓的肝细胞癌一线治疗的前瞻性随机研究。
Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.

引用本文的文献

1
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
2
Depth of Response Predicts Survival in Unresectable Hepatocellular Carcinoma Treated with Immunotherapy: Not All Stable Disease Is Equal.反应深度可预测接受免疫治疗的不可切除肝细胞癌患者的生存情况：并非所有疾病稳定状态都相同。
Liver Cancer. 2025 May 30;14(4):357-364. doi: 10.1159/000546698. eCollection 2025 Aug.
3

本文引用的文献

1
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂联合经动脉化疗栓塞术（三联疗法）治疗不可切除肝细胞癌
Liver Cancer. 2024 Apr 17;13(3):227-234. doi: 10.1159/000538558. eCollection 2024 Jun.
2
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.一项关于经动脉化疗栓塞疗法联合乐伐替尼治疗不可切除中期肝细胞癌的2期前瞻性多中心单臂试验：TACTICS-L试验
Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.
3
Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.
靶向肝癌肿瘤起始细胞的免疫疗法：挑战、机制及新兴治疗前景
Front Immunol. 2025 Jun 11;16:1621243. doi: 10.3389/fimmu.2025.1621243. eCollection 2025.
4
Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.纳米策略与局部区域介入治疗协同作用以增强抗肿瘤免疫力。
Bioact Mater. 2025 May 31;51:634-649. doi: 10.1016/j.bioactmat.2025.05.016. eCollection 2025 Sep.
5
Transarterial Chemoembolization, Molecular Targeted Treatments, and Programmed Death-(Ligand)1 Inhibitors, for Hepatocellular Carcinoma with Lung Metastasis: A Retrospective Cohort Study.经动脉化疗栓塞术、分子靶向治疗及程序性死亡受体-（配体）1抑制剂治疗肺转移肝细胞癌：一项回顾性队列研究
J Hepatocell Carcinoma. 2025 May 23;12:1031-1041. doi: 10.2147/JHC.S509120. eCollection 2025.
6
Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results.免疫检查点抑制剂联合抗血管内皮生长因子/酪氨酸激酶抑制剂与经动脉化疗栓塞术用于局部晚期非转移性肝细胞癌：基于3期临床试验结果的真实世界治疗策略
Liver Cancer. 2025 Mar 29;14(3):241-247. doi: 10.1159/000545594. eCollection 2025 Jun.
7
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.经动脉化疗栓塞术在肝细胞癌免疫靶向治疗时代的作用：一项基于倾向评分匹配的荟萃分析
Front Immunol. 2025 Apr 2;16:1573834. doi: 10.3389/fimmu.2025.1573834. eCollection 2025.
8
T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma.经动脉化疗栓塞联合全身治疗对肝细胞癌的协同作用背景下的T细胞受体谱分析
J Clin Transl Hepatol. 2025 Jan 28;13(1):69-83. doi: 10.14218/JCTH.2024.00238. Epub 2024 Nov 12.
9
Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗-经导管动脉化疗栓塞序贯治疗中期肝细胞癌患者的疗效。
Curr Oncol. 2024 Sep 27;31(10):5821-5831. doi: 10.3390/curroncol31100432.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
4
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.接受联合免疫治疗联合局部区域治疗后达到临床完全缓解的肝细胞癌患者的停药标准
Liver Cancer. 2023 Jul 28;12(4):289-296. doi: 10.1159/000532023. eCollection 2023 Sep.
5
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.阿替利珠单抗联合贝伐单抗加或不加根治性转化治疗经动脉化疗栓塞不适合的中期肝细胞癌患者实现完全缓解和无药状态：一项多中心概念验证研究
Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep.
6
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.TACTICS试验的启示：确立联合/序贯全身治疗与经动脉化疗栓塞实现协同效应的新概念
Liver Cancer. 2022 Oct 6;11(6):487-496. doi: 10.1159/000527404. eCollection 2022 Dec.
7
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者
Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.
8
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.TACTICS的最终结果：一项随机、前瞻性试验，比较经动脉化疗栓塞联合索拉非尼与单纯经动脉化疗栓塞治疗不可切除肝细胞癌患者的疗效。
Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul.
9
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.随机 3 期 LEAP-012 研究：经动脉化疗栓塞联合或不联合仑伐替尼加帕博利珠单抗治疗不可治愈的中期肝细胞癌。
Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.
10
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.一种针对不适合经动脉化疗栓塞术（TACE）的中期肝癌患者的新型治疗策略：先行全身治疗，随后进行根治性转化治疗。
Liver Cancer. 2021 Oct 12;10(6):539-544. doi: 10.1159/000519749. eCollection 2021 Nov.